- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Disease Attributes, +14 more
- Locations
-
- California Research Institute Los Angeles, California, United States
- UCLA Cancer Care Los Angeles, California, United States
- Stanford Cancer Institute Palo Alto, California, United States
- Yale University New Haven, Connecticut, United States
Clinical trial condition
Unresectable Head and Neck Squamous Cell Carcinoma
Explore clinical trials studying Unresectable Head and Neck Squamous Cell Carcinoma. Study availability and eligibility vary by location and protocol.
10 public trials
3 recruiting studies
Unresectable Head and Neck Squamous Cell Carcinoma trial results
NCT05269381
- Conditions
- Adenocarcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, +165 more
- Locations
-
- Mayo Clinic in Florida Jacksonville, Florida, United States
NCT07156227
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +48 more
- Locations
-
- UPMC Hillman Cancer Center LAO Pittsburgh, Pennsylvania, United States
Not Yet Recruiting
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
NCT07576725
- Conditions
- Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +119 more
- Locations
-
- Uganda Cancer Institute Kampala, Uganda
Completed
Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer
NCT04870840
- Conditions
- Carcinoma, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, +35 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03229278
- Conditions
- Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +73 more
- Locations
-
- Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
Active, Not Recruiting
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
NCT01468896
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +8 more
- Locations
-
- MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
Active, Not Recruiting
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06790966
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, HPV Positive Oropharyngeal Squamous Cell Carcinoma, +11 more
- Locations
-
- Mayo Clinic Arizona Phoenix, Arizona, United States
- Marin Cancer Care Greenbrae, California, United States
- University of California, Orange Orange, California, United States
- Yale University New Haven, Connecticut, United States
Active, Not Recruiting
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
NCT03468218
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, +29 more
- Locations
-
- Moffitt Cancer Center Tampa, Florida, United States
- Emory University Hospital Midtown Atlanta, Georgia, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer
NCT04576091
- Conditions
- Carcinoma, Carcinoma, Squamous Cell, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, +52 more
- Locations
-
- Los Angeles General Medical Center Los Angeles, California, United States
- USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
- Northwestern University Chicago, Illinois, United States
- University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States